Analyst Expectations For Collegium Pharmaceutical's Future
Portfolio Pulse from Benzinga Insights
Analyst evaluations of Collegium Pharmaceutical (NASDAQ:COLL) over the last three months show diverse outlooks, with a recent shift towards a more bullish sentiment. The average 12-month price target has increased to $38.5, up from $32.33, indicating a 19.08% rise. Analysts from Needham, Truist Securities, and Jefferies have adjusted their ratings and price targets, reflecting optimism about the company's future performance. Collegium Pharmaceutical's financial indicators such as revenue growth, net margin, ROE, and ROA outperform industry averages, despite a high debt-to-equity ratio.
February 02, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analyst sentiment towards Collegium Pharmaceutical has become more bullish, with an increased average 12-month price target of $38.5. Financial performance indicators are strong, but the company has a high debt-to-equity ratio.
The shift towards a more bullish sentiment among analysts, as evidenced by the increased price target and positive financial performance indicators, suggests a potential short-term positive impact on COLL's stock price. However, the high debt-to-equity ratio introduces a note of caution.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100